A Randomized, Double-Blind, Placebo-Controlled, Two-Session Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of an 16448 in Healthy Males With Premature Ejaculation.
Latest Information Update: 20 Aug 2023
At a glance
- Drugs Retosiban (Primary)
- Indications Premature ejaculation
- Focus Adverse reactions
- Sponsors GlaxoSmithKline; GSK
- 27 May 2009 New trial record